Erythropoiesis-stimulating agent (ESA) biosimilars entered the European market a decade ago, but only one ESA—Retacrit—has launched in the United States, and it did not launch until November 2018. Despite the availability of multiple ESA biosimilars for chronic kidney disease (CKD) for several years, their uptake in Europe has varied from country to country, as well as by drug and manufacturer. With new biosimilars expected to soon enter all markets, it is vital to understand why ESA biosimilar uptake varies in Europe and the likely impact of upcoming biosimilar launches in the United States and Europe. We surveyed nephrologists from France, Germany, and the United States to learn about their experience and familiarity with current biosimilars; the drivers of and barriers to these agents’ uptake; and their expectations for novel biosimilars.
Markets covered: United States, France, and Germany.
Primary research: Online quantitative survey of 92 nephrologists.
- What is the current patient share of CKD biosimilars, and what expectations do nephrologists have for future patient shares?
- How similar do nephrologists believe biosimilars are to their reference brands?
- What factors do nephrologists identify as being the key drivers of and barriers to biosimilar uptake?
- What percentage of biosimilar-treated patients were initiated on a biosimilar, and what percentage were switched from a reference brand?
- What cost reduction is required for a biosimilar to achieve more than a 50% patient share?
Key markets covered:
- United States
Key companies mentioned:
- Johnson & Johnson
- Medice Arzneimittel Putter
- Sandoz (Novartis)
- Stada Arzneimittel
- Vifor Pharma
Key drugs mentioned:
- Epoetin Alfa Hexal